Cargando…

CP-25, a Novel Anti-inflammatory and Immunomodulatory Drug, Inhibits the Functions of Activated Human B Cells through Regulating BAFF and TNF-alpha Signaling and Comparative Efficacy with Biological Agents

Paeoniflorin-6′-O-benzene sulfonate (code: CP-25) was the chemistry structural modifications of Paeoniflorin (Pae). CP-25 inhibited B cells proliferation stimulated by B cell activating factor belonging to the TNF family (BAFF) or Tumor necrosis factor alpha (TNF-alpha). CP-25, Rituximab and Etanerc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Feng, Shu, Jin-Ling, Li, Ying, Wu, Yu-Jing, Zhang, Xian-Zheng, Han, Le, Tang, Xiao-Yu, Wang, Chen, Wang, Qing-Tong, Chen, Jing-Yu, Chang, Yan, Wu, Hua-Xun, Zhang, Ling-Ling, Wei, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743740/
https://www.ncbi.nlm.nih.gov/pubmed/29311935
http://dx.doi.org/10.3389/fphar.2017.00933
_version_ 1783288621353140224
author Zhang, Feng
Shu, Jin-Ling
Li, Ying
Wu, Yu-Jing
Zhang, Xian-Zheng
Han, Le
Tang, Xiao-Yu
Wang, Chen
Wang, Qing-Tong
Chen, Jing-Yu
Chang, Yan
Wu, Hua-Xun
Zhang, Ling-Ling
Wei, Wei
author_facet Zhang, Feng
Shu, Jin-Ling
Li, Ying
Wu, Yu-Jing
Zhang, Xian-Zheng
Han, Le
Tang, Xiao-Yu
Wang, Chen
Wang, Qing-Tong
Chen, Jing-Yu
Chang, Yan
Wu, Hua-Xun
Zhang, Ling-Ling
Wei, Wei
author_sort Zhang, Feng
collection PubMed
description Paeoniflorin-6′-O-benzene sulfonate (code: CP-25) was the chemistry structural modifications of Paeoniflorin (Pae). CP-25 inhibited B cells proliferation stimulated by B cell activating factor belonging to the TNF family (BAFF) or Tumor necrosis factor alpha (TNF-alpha). CP-25, Rituximab and Etanercept reduced the percentage and numbers of CD19(+) B cells, CD19(+)CD20(+) B cells, CD19(+)CD27(+) B cells and CD19(+)CD20(+)CD27(+) B cells induced by BAFF or TNF-alpha. There was significant difference between CP-25 and Rituximab or CP-25 and Etanercept. CP-25 down-regulated the high expression of BAFFR, BCMA, and TACI stimulated by BAFF or TNF-alpha. The effects of Rituximab and Etanercept on BAFFR or BCMA were stronger than that of CP-25. CP-25, Rituximab and Etanercept down-regulated significantly the expression of TNFR1 and TNFR2 on B cell stimulated by BAFF or TNF-alpha. CP-25, Rituximab and Etanercept down-regulated the expression of MKK3, P-p38, P-p65, TRAF2, and p52 in B cells stimulated by BAFF and the expression of TRAF2 and P-p65 in B cells stimulated by TNF-alpha. These results suggest that CP-25 regulated moderately activated B cells function by regulating the classical and alternative NF-κB signaling pathway mediated by BAFF and TNF-alpha-TRAF2-NF-κB signaling pathway. This study suggests that CP-25 may be a promising anti-inflammatory immune and soft regulation drug.
format Online
Article
Text
id pubmed-5743740
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-57437402018-01-08 CP-25, a Novel Anti-inflammatory and Immunomodulatory Drug, Inhibits the Functions of Activated Human B Cells through Regulating BAFF and TNF-alpha Signaling and Comparative Efficacy with Biological Agents Zhang, Feng Shu, Jin-Ling Li, Ying Wu, Yu-Jing Zhang, Xian-Zheng Han, Le Tang, Xiao-Yu Wang, Chen Wang, Qing-Tong Chen, Jing-Yu Chang, Yan Wu, Hua-Xun Zhang, Ling-Ling Wei, Wei Front Pharmacol Pharmacology Paeoniflorin-6′-O-benzene sulfonate (code: CP-25) was the chemistry structural modifications of Paeoniflorin (Pae). CP-25 inhibited B cells proliferation stimulated by B cell activating factor belonging to the TNF family (BAFF) or Tumor necrosis factor alpha (TNF-alpha). CP-25, Rituximab and Etanercept reduced the percentage and numbers of CD19(+) B cells, CD19(+)CD20(+) B cells, CD19(+)CD27(+) B cells and CD19(+)CD20(+)CD27(+) B cells induced by BAFF or TNF-alpha. There was significant difference between CP-25 and Rituximab or CP-25 and Etanercept. CP-25 down-regulated the high expression of BAFFR, BCMA, and TACI stimulated by BAFF or TNF-alpha. The effects of Rituximab and Etanercept on BAFFR or BCMA were stronger than that of CP-25. CP-25, Rituximab and Etanercept down-regulated significantly the expression of TNFR1 and TNFR2 on B cell stimulated by BAFF or TNF-alpha. CP-25, Rituximab and Etanercept down-regulated the expression of MKK3, P-p38, P-p65, TRAF2, and p52 in B cells stimulated by BAFF and the expression of TRAF2 and P-p65 in B cells stimulated by TNF-alpha. These results suggest that CP-25 regulated moderately activated B cells function by regulating the classical and alternative NF-κB signaling pathway mediated by BAFF and TNF-alpha-TRAF2-NF-κB signaling pathway. This study suggests that CP-25 may be a promising anti-inflammatory immune and soft regulation drug. Frontiers Media S.A. 2017-12-22 /pmc/articles/PMC5743740/ /pubmed/29311935 http://dx.doi.org/10.3389/fphar.2017.00933 Text en Copyright © 2017 Zhang, Shu, Li, Wu, Zhang, Han, Tang, Wang, Wang, Chen, Chang, Wu, Zhang and Wei. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Feng
Shu, Jin-Ling
Li, Ying
Wu, Yu-Jing
Zhang, Xian-Zheng
Han, Le
Tang, Xiao-Yu
Wang, Chen
Wang, Qing-Tong
Chen, Jing-Yu
Chang, Yan
Wu, Hua-Xun
Zhang, Ling-Ling
Wei, Wei
CP-25, a Novel Anti-inflammatory and Immunomodulatory Drug, Inhibits the Functions of Activated Human B Cells through Regulating BAFF and TNF-alpha Signaling and Comparative Efficacy with Biological Agents
title CP-25, a Novel Anti-inflammatory and Immunomodulatory Drug, Inhibits the Functions of Activated Human B Cells through Regulating BAFF and TNF-alpha Signaling and Comparative Efficacy with Biological Agents
title_full CP-25, a Novel Anti-inflammatory and Immunomodulatory Drug, Inhibits the Functions of Activated Human B Cells through Regulating BAFF and TNF-alpha Signaling and Comparative Efficacy with Biological Agents
title_fullStr CP-25, a Novel Anti-inflammatory and Immunomodulatory Drug, Inhibits the Functions of Activated Human B Cells through Regulating BAFF and TNF-alpha Signaling and Comparative Efficacy with Biological Agents
title_full_unstemmed CP-25, a Novel Anti-inflammatory and Immunomodulatory Drug, Inhibits the Functions of Activated Human B Cells through Regulating BAFF and TNF-alpha Signaling and Comparative Efficacy with Biological Agents
title_short CP-25, a Novel Anti-inflammatory and Immunomodulatory Drug, Inhibits the Functions of Activated Human B Cells through Regulating BAFF and TNF-alpha Signaling and Comparative Efficacy with Biological Agents
title_sort cp-25, a novel anti-inflammatory and immunomodulatory drug, inhibits the functions of activated human b cells through regulating baff and tnf-alpha signaling and comparative efficacy with biological agents
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743740/
https://www.ncbi.nlm.nih.gov/pubmed/29311935
http://dx.doi.org/10.3389/fphar.2017.00933
work_keys_str_mv AT zhangfeng cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents
AT shujinling cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents
AT liying cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents
AT wuyujing cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents
AT zhangxianzheng cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents
AT hanle cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents
AT tangxiaoyu cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents
AT wangchen cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents
AT wangqingtong cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents
AT chenjingyu cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents
AT changyan cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents
AT wuhuaxun cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents
AT zhanglingling cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents
AT weiwei cp25anovelantiinflammatoryandimmunomodulatorydruginhibitsthefunctionsofactivatedhumanbcellsthroughregulatingbaffandtnfalphasignalingandcomparativeefficacywithbiologicalagents